Mitzi Thompson, NP
Women's Health · Roseburg, ORNPI 1912987926
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $326 of the $533 with a category attached, or 61.1%. 8 manufacturers reported payments, led by Astellas Pharma US Inc at 45.8% of the total. Reporting peaked in 2023 at $246 and has fallen 85.6% since, to $35 in 2025.
Across 21 payments — averaging $25.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$244
- AbbVie$84
- Hologic Sales And Service, LLC$54
- Coopersurgical, Inc.$51
- Pfizer$35
- Ascend Therapeutics US, LLC$24
- plus $41 from 2 others
What the payments were for
- Food & beverage$32661%
- Education$20739%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 5 | $244 |
| AbbVie | 4 | $84 |
| Hologic Sales And Service, LLC | 3 | $54 |
| Coopersurgical, Inc. | 3 | $51 |
| Pfizer | 2 | $35 |
| Ascend Therapeutics US, LLC | 2 | $24 |
| Organon | 1 | $22 |
| Evofem Biosciences, Inc. | 1 | $19 |
How this compares
$533 in reported general payments places this provider in the 80th percentile of 57 women's health providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 138 | $10,919 |
| DottiEstradiol | 52 | $7,317 |
| Estradiol (Twice Weekly)Estradiol | 52 | $6,476 |
| ZafemyNorelgestromin/Ethin.Estradiol | 19 | $2,132 |
| ProgesteroneProgesterone, Micronized | 58 | $2,069 |
| YuvafemEstradiol | 12 | $1,910 |
| Estradiol (Once Weekly)Estradiol | 11 | $1,527 |
| ValacyclovirValacyclovir Hcl | 24 | $594 |
| Betamethasone Dipropionate | 12 | $420 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 25 | $266 |
| Medroxyprogesterone Acetate | 18 | $120 |
Paid to pharmacies, not to this prescriber.
Other women's health in Roseburg
- Jennifer BzowyRoseburg$840
- Jennifer Hanlon-WildeThe Dalles$3K
- Sheryl HorwitzPortland$1K
- Michaela FrenchSpringfield$916
- Jessica BenedictHillsboro$879
- Kimberly LarsonMedford$845
- Crystal LindahlGrants Pass$830
- Nancy MacyTualatin$803
- Jade CarboyBend$705
- Shoshana FarberDallas$691
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.